245 related articles for article (PubMed ID: 26755074)
1. Epidermal growth factor receptor targeting and challenges in glioblastoma.
Thorne AH; Zanca C; Furnari F
Neuro Oncol; 2016 Jul; 18(7):914-8. PubMed ID: 26755074
[TBL] [Abstract][Full Text] [Related]
2. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
[TBL] [Abstract][Full Text] [Related]
3. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.
Roth P; Weller M
Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii14-9. PubMed ID: 25342600
[TBL] [Abstract][Full Text] [Related]
4. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
Guo G; Narayan RN; Horton L; Patel TR; Habib AA
Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
Gao Q; Lei T; Ye F
Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
[TBL] [Abstract][Full Text] [Related]
6. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
7. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
Masui K; Tanaka K; Ikegami S; Villa GR; Yang H; Yong WH; Cloughesy TF; Yamagata K; Arai N; Cavenee WK; Mischel PS
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9406-11. PubMed ID: 26170313
[TBL] [Abstract][Full Text] [Related]
8. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma.
Liu F; Mischel PS
Wiley Interdiscip Rev Syst Biol Med; 2018 Jan; 10(1):. PubMed ID: 28892308
[TBL] [Abstract][Full Text] [Related]
9. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Chen Y; Li R; Pan M; Shi Z; Yan W; Liu N; You Y; Zhang J; Wang X
J Neurooncol; 2017 Jul; 133(3):477-485. PubMed ID: 28501897
[TBL] [Abstract][Full Text] [Related]
10. Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
Velpula KK; Guda MR; Sahu K; Tuszynski J; Asuthkar S; Bach SE; Lathia JD; Tsung AJ
Oncotarget; 2017 May; 8(22):35639-35655. PubMed ID: 28410193
[TBL] [Abstract][Full Text] [Related]
11. EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.
Keller S; Schmidt MHH
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629170
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.
Huang PH; Mukasa A; Bonavia R; Flynn RA; Brewer ZE; Cavenee WK; Furnari FB; White FM
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12867-72. PubMed ID: 17646646
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor in glioblastoma.
Zawrocki A; Biernat W
Folia Neuropathol; 2005; 43(3):123-32. PubMed ID: 16245205
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
18. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
19. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
[TBL] [Abstract][Full Text] [Related]
20. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]